ONO-3403 mesylate | Serine Protease Inhibitor | CAS#181586-07-2

MedKoo Cat#: 525785 | Name: ONO-3403 mesylate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ono 3403 is a synthetic serine protease inhibitor hat inhibits lipopolysaccharide-induced tumor necrosis factor-{alpha} and nitric oxide production and protects mice from lethal endotoxic shock. Oral administration of the potent serine protease inhibitor ONO-3403 has an antitumor effect on malignant tumors suggested by the growth inhibition of mouse skin tumors in research.

Chemical Structure

ONO-3403 mesylate

CAS#181586-07-2

Theoretical Analysis

MedKoo Cat#: 525785

Name: ONO-3403 mesylate

CAS#: 181586-07-2

Chemical Formula: C26H31N3O8S

Exact Mass: 545.1832

Molecular Weight: 545.60

Elemental Analysis: C, 57.24; H, 5.73; N, 7.70; O, 23.46; S, 5.88

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Ono-3403; Ono3403; Ono 3403; ONO-3403 mesylate;

IUPAC/Chemical Name

4-carbamimidoylphenyl (E)-4-(3-(allyl(2-ethoxy-2-oxoethyl)amino)-2-methyl-3-oxoprop-1-en-1-yl)benzoate methanesulfonate

InChi Key

PKBZGVVSSNNHGY-INTLEYBYSA-N

InChi Code

InChI=1S/C25H27N3O5.CH4O3S/c1-4-14-28(16-22(29)32-5-2)24(30)17(3)15-18-6-8-20(9-7-18)25(31)33-21-12-10-19(11-13-21)23(26)27;1-5(2,3)4/h4,6-13,15H,1,5,14,16H2,2-3H3,(H3,26,27);1H3,(H,2,3,4)/b17-15+;

SMILES Code

O=C(OC1=CC=C(C(N)=N)C=C1)C2=CC=C(/C=C(C)/C(N(CC(OCC)=O)CC=C)=O)C=C2.CS(=O)(O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 545.60 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Tumurkhuu G, Koide N, Hiwasa T, Ookoshi M, Dagvadorj J, Abu Shadat Mohammod Noman, Iftakhar-E-Khuda I, Naiki Y, Komatsu T, Yoshida T, Yokochi T. ONO 3403, a synthetic serine protease inhibitor, inhibits lipopolysaccharide-induced tumor necrosis factor-{alpha} and nitric oxide production and protects mice from lethal endotoxic shock. Innate Immun. 2011 Feb;17(1):97-105. doi: 10.1177/1753425909353641. Epub 2009 Dec 18. PubMed PMID: 20023007. 2: Ohkoshi M, Okuda S. Growth inhibition of mouse autochthonous skin cancer by oral administration of new serine protease inhibitor ONO-3403. Anticancer Res. 2002 Mar-Apr;22(2A):821-3. PubMed PMID: 12014657. 3: Hiwasa T, Kondo K, Nakagawara A, Ohkoshi M. Potent growth-suppressive activity of a serine protease inhibitor, ONO-3403, toward malignant human neuroblastoma cell lines. Cancer Lett. 1998 Apr 24;126(2):221-5. PubMed PMID: 9585070. 4: Ohkoshi M, Denda T, Hiwasa T. Growth-suppressive activities of serine protease inhibitors, FOY-305, ONO-3403 and FO-349 toward human carcinoma cells. Oncol Rep. 1997 May-Jun;4(3):521-3. PubMed PMID: 21590090. 5: Hiwasa T, Shimada H, Ochiai T, Liu TL, Yuasa Y, Takiguchi M, Ohkoshi M. Decrease in growth factor receptors after treatment with serine protease inhibitor ONO-3403. Int J Oncol. 2002 Apr;20(4):797-802. PubMed PMID: 11894127. 6: Ohkoshi M, Okuda S. Growth inhibition of mouse skin tumor by serine protease inhibitor ONO-3403. Anticancer Res. 2001 May-Jun;21(3B):1803-8. PubMed PMID: 11497262. 7: Hiwasa T, Ohkoshi M. Growth-suppressive activities of serine protease inhibitors, ONO-3403 and ONO-5046, toward normal and transformed murine fibroblasts. Anticancer Res. 1996 Jul-Aug;16(4A):1823-6. PubMed PMID: 8712707.